| Symbol | KALV |
|---|---|
| Name | KALVISTA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 55 CAMBRIDGE PARKWAY,SUITE 901 EAST, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 857 999-0075 |
| Fax | — |
| — | |
| Website | https://www.kalvista.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001348911 |
| Description | KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The companys product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003487 <b>Size:</b> 12 KB
Read morePalleiko Benjamin L 🟡 adjusted position in 3.3K shares (1 derivative) of KalVista Pharmaceuticals, Inc. (KALV) at $26.71 Transaction Date: May 11, 2026 | Filing ID: 000007
Read moreNew Form SC 14D9 - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001140361-26-021078 <b>Size:</b> 672 KB
Read moreNew Form SCHEDULE 13G - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001104659-26-060314 <b>Size:</b> 10 KB
Read moreNew Form SC TO-T - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001140361-26-020935 <b>Size:</b> 12 MB
Read moreNew Form SCHEDULE 13G/A - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-01 <b>AccNo:</b> 0001104659-26-054259 <b>Size:</b> 18 KB
Read moreKalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Read moreNew Form SC14D9C - KalVista Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-29 <b>AccNo:</b> 0001140361-26-017860 <b>Size:</b> 194 KB
Read moreShareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
Read moreKALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Read more